Skip to content

Wheezometer™ Exploratory (WM) Field Study

Wheezometer™ Exploratory (WM) Field Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01156818
Enrollment
40
Registered
2010-07-05
Start date
2010-07-31
Completion date
2011-12-31
Last updated
2011-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Sounds, Wheezing

Keywords

Wheeze measurements

Brief summary

Karmel Sonix Ltd has developed the Personal WheezoMeter a hand-held pulmonary sounds analyzer that utilizes contact sensors to acquire, amplify, filter, record and quantify the presence of wheezing. When used to monitor conditions such as asthma, this device should be used under the direction of a physician or licensed healthcare professional. The device is intended for use with pediatric and adult patients in both home and clinical settings. The purpose of the study is to determine whether Wz% and change in Wz% correlate with symptoms and change in symptoms at least as well as FEV1 and change in FEV1.0. Additional information to be obtained from the study will be to determine whether there is a symptom threshold at which a patient seeks rescue medications and if so, to determine the value of Wz% and FEV1.0 at this point (Wz%, FEV1.0 thresholds). The study will also provide information on the within patient and whole group correlations between Wz% and FEV.

Interventions

None listed

Sponsors

KarmelSonix Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
8 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Physician diagnosed asthma. * Poorly controlled asthma as per GINA Guidelines with frequent (i.e. \>5/week) use of reliever medications. * Adequate comprehension level and demonstrated ability to perform unsupervised spirometry, wheezometry and use the symptom diary. * Age range 8-80. Patients over 40 will only be included if they are lifetime non-smokers, who have demonstrated reversibility of airway obstruction (at least 12% improvement in FEV1.0 after bronchodilator). * All patients included in the study will be routinely receiving either a short acting bronchodilator or a long acting bronchodilator twice daily as part of their regular medication. Additional doses of bronchodilator will be taken on an as needed basis. No change in regular medication will be made for the purposes of the study. * Subject or subject's parents/guardians is/are able to comprehend and give informed consent for participation in the study. Consent of treating physician.

Exclusion criteria

* Inability to perform spirometry and/or Wheezometry. Skin Disorder (burn, infection, or allergy) over upper chest (Child) or neck (Adult). * Patients with other diseases, which in the opinion of the treating physician would interfere with the management of asthma and performance of the study according to the protocol. * Hospitalization at recruitment, \[patients who get admitted while participating will continue to participate\]. P- hysician objection.

Design outcomes

Primary

MeasureTime frame
Wz% change in response to BD. Symptom score by e-Diary; Spirometer - FEV1.0/FVC/PEF/MEF50 with automated storage and timing2 weeks

Secondary

MeasureTime frame
Correlate Wz% to FEV1.0: within patient correlation2 weeks

Countries

United States

Contacts

Primary ContactRoss Wilson
rossw@karmelsoinx.com909-989-0033

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026